Industry Partnerships
Who We Are and What We Do
T1D Exchange is a nonprofit organization that drives improved outcomes in the treatment of type 1 diabetes (T1D) and type 2 diabetes (T2D). In collaboration with our partners, we collect and analyze data to advance diabetes research, identify gaps and unmet needs in diabetes care, refine best practices, and ultimately improve the quality of life for all people living with diabetes.
How We Help Research Partners in the Diabetes Industry
Custom Research Projects
T1D Exchange works with diabetes researchers to design, deploy, analyze, and report on custom research projects to help them meet their goals.
With our research partners, we carry out a wide variety of diabetes research studies, including:
- Interviews and focus groups
- Online surveys
- Virtual studies
- Quantitative Analysis
- Qualitative Studies and Analysis
- Performance Improvement Analysis
- Implementation Project Analysis
Study Recruitment
T1D Exchange accelerates research through our successful study recruitment efforts. With more than 45,000 people directly impacted by T1D in the T1D Exchange Registry and Online Community, we are connected to a community that has a passion for participating in research.
Over the past few years, we have helped to quickly fill dozens of diabetes research studies, sometimes within just a matter of minutes. By reducing barriers to research participation, we have recruited several thousands of people with diabetes into research studies for our partners.
Custom Research Success Stories
T1D Exchange and Zealand Pharmaceuticals gathered insights from people with T1D on the actual experience of using glucagon and the emotions that may come with it.
By combining surveys with associated CGM data for over 1,000 individuals, including time in range analysis, we have assessed perceptions of severe hypoglycemia and the realities of its frequency, severity, and impact.
We examined unmet needs and barriers to CGM usage in both T1D and T2D to help guide a company looking to bring a new CGM device to market.
With some of our T1D Exchange Quality Improvement Collaborative centers, we examined operational barriers and drivers to smart insulin pen use to help inform the manufacturer of opportunities to reduce system friction and improve uptake.